임신부에서 약물의 안전사용을 위한 연구의 필요성
Necessity of Research for Safe Drug use in Pregnant Women
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
The thalidomide tragedy in the 1960s has resulted in a perpetuation of a certain perception amongst physicians and pregnant women that the use of medication during pregnancy is a potential teratogen. Consequently, physicians hesitate in prescribing medication to pregnant women. In addition, pregnant women often refuse medication despite therapeutic necessity because of this existing perception. Recently there have been frequent adverse pregnancy outcomes related to the recurrence of chronic diseases, such as hypertension and diabetes, following pregnancy in older women. And there are lots of unnecessary termination of pregnancy due to the of information of medication exposed to medication following over 50% of unintended pregnancy. In light of this, better dissemination of information regarding the safe usage of medication for pregnant women is required. This would not only be cost-effective in terms of medical expenditure, but also prove beneficial for the treatment of diseases. In addition, Korea needs to adapt to the increasing changes of the international information system regarding supporting the safe usage of medication during pregnancy. An example of this is shown by the recent changes to the labeling of medication by the United States Food and Drug Administration. The new labeling includes information on the risk of usage, rather than just an arbitrary alphabetic classification of B, C, D, or X. Furthermore, this information is limited in Korea because of the lack of research, which in turn is due to several limitations on ethics and methodology, as well as present regulations on the research of pregnant women. From this, we can learn that government support is critical for the establishment of research so that we can alter the perception that all medication is harmful to pregnant women.
Abstract
The thalidomide tragedy in the 1960s has resulted in a perpetuation of a certain perception amongst physicians and pregnant women that the use of medication during pregnancy is a potential teratogen. Consequently, physicians hesitate in prescribing medication to pregnant women. In addition, pregnant women often refuse medication despite therapeutic necessity because of this existing perception. Recently there have been frequent adverse pregnancy outcomes related to the recurrence of chronic diseases, such as hypertension and diabetes, following pregnancy in older women. And there are lots of unnecessary termination of pregnancy due to the of information of medication exposed to medication following over 50% of unintended pregnancy. In light of this, better dissemination of information regarding the safe usage of medication for pregnant women is required. This would not only be cost-effective in terms of medical expenditure, but also prove beneficial for the treatment of diseases. In addition, Korea needs to adapt to the increasing changes of the international information system regarding supporting the safe usage of medication during pregnancy. An example of this is shown by the recent changes to the labeling of medication by the United States Food and Drug Administration. The new labeling includes information on the risk of usage, rather than just an arbitrary alphabetic classification of B, C, D, or X. Furthermore, this information is limited in Korea because of the lack of research, which in turn is due to several limitations on ethics and methodology, as well as present regulations on the research of pregnant women. From this, we can learn that government support is critical for the establishment of research so that we can alter the perception that all medication is harmful to pregnant women.
참고문헌 (25)
- Azar M, "Management of pregnancy in women with type 1 diabetes", Minerva Endocrinol, 38, pp.339~349 (2013)
- Blattner CM, "Understanding the new FDA pregnancy and lactation labeling rules", Int J Womens Dermatol, 2(1), pp.5~7 (2016)
- Ernst FR, "Drug-related morbidity and mortality:updating the cost-of-illness model", J Am Pharm Assoc, 41, pp.192~199 (2001)
- "Pregnancy exposure registries"[URL]
- Grigoriadis S, "The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis", J Clin Psychiatry, 74, pp.e321~e341 (2013)
- Haddow JE, "Maternal. Thyroid deficiency during pregnancy and subsequent neuropsychological development of the child", N Engl J Med, 341, pp.549~555 (1999)
- 한정열, "임신 제일삼분기 약물 및 진단용 방사선 노출 임신부에서 기형 발생 위험에 관한 근거중심적 상담의 효과", Obstetrics & Gynecology Science, 45(1), pp.18~18 (2002), 대한산부인과학회
- 한정열, "인공임신중절예방을 위한 한국마더세이프전문상담센터 운영에 따른 비용-편익", 한국모자보건학회지, 19(2), pp.289~295 (2015), 한국모자보건학회[DOI]
- "Phocomelia"[URL]
- Herring C, "Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women's Hospital", Int J Pharm Pract, 18(4), pp.226~229 (2010)
- Ito T, "Deciphering the mystery of thalidomide teratogenicity", Congen Anom, 52, pp.1~7 (2012)
- Janer G, "A retrospective analysis of developmental toxicity studies in rat and rabbit: what is the added value of the rabbit as an additional test species?", Regul Toxicol Pharmacol, 50(2), pp.206~217 (2008)
- Jha AK, "Identifying hospital admissions due to adverse drug events using a computer-based monitor", Pharmacoepidemiol Drug Saf, 10, pp.113~119 (2001)
- National survey and prevention plan of Artificial Abortion Ministry of Health and Welfare 2004, "Kim HJ", ~ (2004)
- "Contraindication of pregnant women"[URL]
- Lo WY, "Teratogenicity of recently introduced medications in human pregnancy", Obstet Gynecol, 100, pp.465~473 (2002)
- Lupattelli A, "Medication use in pregnancy: a cross-sectional, multinational web-based study", BMJ open, 4(2), pp.e004365~ (2014)
- Mazer-Amirshahi M, "Trends in pregnancy labeling and data quality for US-approved pharmaceuticals", Am J Obstet Gynecol, 211, pp.690~ (2014)
- Mitchell AA, "National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008", Am J Obstet Gynecol, 205(1), pp.51~ (2011)
- Murphy VE, "Managing asthma in pregnancy", Breathe (Sheff), 11(4), pp.258~267 (2015)
- Neutel CI, "Measuring drug effectiveness by default: the case of Bendectin", Can J Public Health, 86(1), pp.66~70 (1995)
- Support Plans of Clinical Trials and Drug Review for Pediatrics, Geriatrics and Females, "Oh JM", KFDA, ~ (2015)
- Schardein JL, "Chemically induced birth defects", pp.100~ (2000), Marcel Dekker
- Vargesson Neil, "Thalidomide‐induced teratogenesis: History and mechanisms", Birth Defects Res C Embryo Today, 105(2), pp.140~156 (2015)
- Yook JH, "Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin", Clin Toxicol (Phila), 50(10), pp.896~901 (2012)